MiniMed Group Inc. (MMED) 12-Month Stock Forecast & Price Target Cone

The per the Roarable RQD rating, MMED scores 46 out of 100, a D grade labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 6/20 (ROIC -3.9%; FCF yield -7.75%), Whale 13F Flow at 11/20 (institutional accumulation and options positioning), Insider Conviction at 6/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 9/20 (Beta 1.05; sector sensitivity), and Forensic Balance Sheet at 14/20 (Altman Z 4.82; Piotroski F 5/9; Debt/Equity 0.11).

Read together, the cash-generation and insider pillars are the weakest, while the balance sheet is the strongest. For a prospective investor, the upside case rests mainly on balance-sheet resilience and the institutional-flow pillar, which are the two components scoring above their midpoint. The valuation tradeoff is material: the company reports negative EPS (TTM) of -1.18 and a negative FCF yield, yet the forward P/E is 24, so the market is pricing earnings improvement that the trailing data does not yet show. The rating signals that, on current evidence, the cash engine and insider activity do not confirm that improvement. This is an analytical framing, not personalized advice.

Per the SEC financials, operating and net losses widened across the three reported periods while revenue rose from $2469.0M to $3102.0M. Per the market data, gross margin is 54.2%, operating margin -6.1%, and net margin -10.7%, with ROIC at -3.9%. Per the Roarable RQD rating, the Altman Z-Score is 4.82, the Piotroski F-Score 5/9, and Debt/Equity 0.11. Reported debt declined from $762.4M (FY 2024) to $396.4M (FY 2025), while FY 2025 cash is $10.0M.

• Medtronic exchange offer: Per the news wire, Medtronic announced final results of the MiniMed Group exchange offer, and a separate report describes the offer as oversubscribed with an 18.3% acceptance rate. This is the most concrete corporate event in the data.
• Director share exchange: A Stock Titan report describes a MiniMed director receiving 836 shares in exchange for 182 Medtronic shares.
• Short interest: A Protos report states that 99% of MiniMed's float has been sold short, a notable risk-watch item.
• Analyst action: A MarketBeat report describes a price target raise at Mizuho, flagged as a catalyst in the feed.
• Market commentary: A Yahoo Finance piece covers differing views on MMED and Medtronic from a media commentator.

Proprietary signals: Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are recorded.

• What are the company's core product lines, revenue segments, and customer concentration?
• Why is trailing P/E unavailable while forward P/E is 24 with negative trailing EPS, and what earnings path underlies that forward figure?
• What drove the decline in reported debt from $762.4M to $396.4M, and how is it funded given FY 2025 cash of $10.0M?
• What are the terms and strategic rationale of the Medtronic exchange offer, and how does it affect MMED's float and governance?
• What is the basis for the reported 99% short-float figure, and how reliable is that metric?